CELGENE CORP COM (CELG) : Gw Henssler Associates Ltd reduced its stake in CELGENE CORP COM by 3.12% during the most recent quarter end. The investment management company now holds a total of 178,808 shares of CELGENE CORP COM which is valued at $19,761,860 after selling 5,749 shares in CELGENE CORP COM , the firm said in a disclosure report filed with the SEC on Apr 21, 2016.CELGENE CORP COM makes up approximately 2.30% of Gw Henssler Associates Ltd’s portfolio.
CELGENE CORP COM closed down -1.4 points or -1.30% at $106.15 with 59,08,642 shares getting traded on Wednesday. Post opening the session at $107.9, the shares hit an intraday low of $105.82 and an intraday high of $108.11 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
Other Hedge Funds, Including , Valley National Advisers Inc boosted its stake in CELG in the latest quarter, The investment management firm added 851 additional shares and now holds a total of 8,615 shares of CELGENE CORP COM which is valued at $952,130. CELGENE CORP COM makes up approx 0.50% of Valley National Advisers Inc’s portfolio. Butensky Cohen Financial Security Inc sold out all of its stake in CELG during the most recent quarter. The investment firm sold 29 shares of CELG which is valued $3,205.Rhenman Partners Asset Management Ab boosted its stake in CELG in the latest quarter, The investment management firm added 16,000 additional shares and now holds a total of 120,000 shares of CELGENE CORP COM which is valued at $13,262,400. CELGENE CORP COM makes up approx 2.40% of Rhenman Partners Asset Management Ab’s portfolio.Benin Management Corp boosted its stake in CELG in the latest quarter, The investment management firm added 790 additional shares and now holds a total of 4,435 shares of CELGENE CORP COM which is valued at $490,156. CELGENE CORP COM makes up approx 0.26% of Benin Management Corp’s portfolio.Capstone Asset Management Co reduced its stake in CELG by selling 1,360 shares or 1.05% in the most recent quarter. The Hedge Fund company now holds 128,014 shares of CELG which is valued at $13,741,023. CELGENE CORP COM makes up approx 0.39% of Capstone Asset Management Co’s portfolio.
On the company’s financial health, CELGENE CORP COM reported $1.18 EPS for the quarter, missing the analyst consensus estimate by $ -0.03 based on the information available during the earnings call on Jan 28, 2016. Analyst had a consensus of $1.21. The company had revenue of $2563.30 million for the quarter, compared to analysts expectations of $2548.22 million. The company’s revenue was up 22.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.01 EPS.
Many Wall Street Analysts have commented on CELGENE CORP COM. Citigroup Initiated CELGENE CORP COM on Feb 25, 2016 to “Buy”, Price Target of the shares are set at $130.Shares were Reiterated by RBC Capital Mkts on Jan 29, 2016 to “Outperform” and Lowered the Price Target to $ 135 from a previous price target of $150 .
Celgene Corporation (Celgene) together with its subsidiaries is an integrated biopharmaceutical company engaged primarily in the discovery development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Companys primary commercial stage products include REVLIMID (lenalidomide) ABRAXANE POMALYST/IMNOVID VIDAZA azacitidine for injection (generic version of VIDAZA) THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States) OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies targeting areas including intracellular signaling pathways protein homeostasis and epigenetics in cancer and immune cells immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies.